{"id":"amoxicillin-clavulinic-acid","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Diarrhea"},{"rate":"3-5","effect":"Nausea"},{"rate":"1-3","effect":"Vomiting"},{"rate":"1-3","effect":"Rash"},{"rate":"2-4","effect":"Abdominal pain"},{"rate":"1-2","effect":"Allergic reaction"}]},"_chembl":{"chemblId":"CHEMBL1082","moleculeType":"Small molecule","molecularWeight":"365.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amoxicillin is a beta-lactam antibiotic that disrupts peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis and death. Clavulanic acid is a beta-lactamase inhibitor that irreversibly binds to and inactivates bacterial beta-lactamase enzymes, preventing them from breaking down amoxicillin and extending its spectrum of activity against beta-lactamase-producing organisms.","oneSentence":"Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while clavulanic acid protects amoxicillin from degradation by beta-lactamase enzymes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:57.049Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections caused by beta-lactamase-producing organisms (respiratory tract infections, urinary tract infections, skin and soft tissue infections, otitis media)"},{"name":"Community-acquired pneumonia"},{"name":"Acute bacterial sinusitis"}]},"trialDetails":[{"nctId":"NCT04198129","phase":"PHASE1","title":"The Evaluation of Postoperative Antibiotics in Non-Infected Mandible Fractures","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2020-10-01","conditions":"Jaw Fractures, Infection","enrollment":13},{"nctId":"NCT00649831","phase":"PHASE3","title":"A Multicentre, Randomised, Open-Label Study To Compare The Efficacy And Safety Of Azithromycin For 5 Days With Those Of Amoxicillin-Clavulanic Acid In Patients With Chronic Bronchitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-10","conditions":"Bronchitis, Chronic","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Amoxicillin/clavulinic acid","genericName":"Amoxicillin/clavulinic acid","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while clavulanic acid protects amoxicillin from degradation by beta-lactamase enzymes. Used for Bacterial infections caused by beta-lactamase-producing organisms (respiratory tract infections, urinary tract infections, skin and soft tissue infections, otitis media), Community-acquired pneumonia, Acute bacterial sinusitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}